ASTRAZENECA PLC

Listed Company
AZNCIK 0000901832NYSELarge AcceleratedPharmaceutical PreparationsX0GBFY ends Dec 31
Period
FY 2025
Revenue
Net Income
$10.23B
Total Assets
$114.07B
Equity
Shares Out
Op. Cash Flow

Business

ASTRAZENECA PLC is a global, innovation-driven biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. It offers a broad portfolio including small molecules, biologics, antibody‑drug conjugates, monoclonal antibodies, gene‑ and RNA‑based therapies, and vaccines across multiple therapeutic areas. Key business segments comprise Oncology; Cardiovascular, Renal & Metabolism (CVRM); Respiratory & Immunology; Vaccines & Immune Therapies; Rare Disease; and Other medicines. The company markets products and conducts R&D worldwide, distributing through direct commercial operations, partnerships and third‑party distributors across the US, Emerging Markets (including China), Europe and other regions.

Summary from filing dated 2025-02-18

Financials

Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.

Revenue
Net income$10.23B
Total assets$114.07B
Total liabilities$65.36B
Stockholders' equity
Operating cash flow

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro